Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* Reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with a history of myocardial infarction (MI) or acute coronary syndrome (ACS).
* In combination with aspirin, for the prevention of atherothrombotic events in patients with ACS.
## Adult Dosing
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for up to 12 months, or longer in specific situations based on clinical assessment and risk factors. In some regions, a 60 mg twice-daily dose is used for long-term maintenance in patients who have had an MI at least 1 year prior.
## Pediatric Dosing
* No established pediatric dosing.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution in patients with moderate to severe hepatic impairment due to increased exposure. No dose adjustment.
* **Renal Impairment:** No dose adjustment is required for mild, moderate, or severe renal impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its components.
* Concomitant use with strong CYP3A4 inhibitors is generally not recommended.
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including fatal and life-threatening), bradycardia, syncope, ventricular pauses, hyperuricemia, increased serum creatinine.
* **Serious:** Major bleeding, particularly gastrointestinal.
## Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin):** May increase ticagrelor plasma concentrations. Concomitant use with strong inhibitors is generally not recommended.
* **CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine):** May decrease ticagrelor plasma concentrations.
* **Statins:** Ticagrelor can inhibit OATP1B1/1B3, potentially increasing statin exposure. Monitor for statin-related adverse effects.
* **Digoxin:** Ticagrelor can increase digoxin concentrations; monitor digoxin levels and for signs of toxicity.
* **Anticoagulants (e.g., warfarin, heparin, direct oral anticoagulants):** Increased risk of bleeding. Use with caution and monitor for bleeding.
* **Aspirin:** Concomitant use increases the risk of bleeding.
## Monitoring
* **Bleeding:** Closely monitor for any signs or symptoms of bleeding.
* **Renal Function:** Monitor serum creatinine, especially in patients with pre-existing renal dysfunction.
* **Hepatic Function:** Monitor liver function tests in patients with hepatic impairment.
* **Heart Rate:** Monitor for bradycardia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, which may allow for faster platelet function recovery compared to irreversible inhibitors if surgery is required.
* Dyspnea is a common side effect and is usually not associated with pulmonary pathology. If it persists or is severe, consider discontinuation.
* Discontinuation of ticagrelor, especially within the first year of ACS, increases the risk of thrombotic events. Discuss risks and benefits with the patient before stopping.
* Ticagrelor should be taken with or without food.
* Avoid concomitant use of ticagrelor with prasugrel or clopidogrel.
***
*Disclaimer: This information is intended for clinical use and does not replace professional judgment. Always consult the most current prescribing information and relevant guidelines before making clinical decisions.*
